Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Union Hospital · Huazhong University of Science and Technology · +5 more institutions
Abstract
Abstract Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of cancer cells, which has become one of the hotspots for the research and development of anticancer drugs. Since the first ADC, Mylotarg ® (gemtuzumab ozogamicin), was approved in 2000 by the US Food and Drug Administration (FDA), there have been 14 ADCs received market approval so far worldwide. Moreover, over 100 ADC candidates have been investigated in clinical stages at present. This kind of new anti-cancer…
Citation impact
- FWCI
- 136.14
- Percentile
- 100%
- References
- 278
Authors
5- ZFZhiwen FuCorresponding
Union Hospital, Huazhong University of Science and Technology
- SLShijun Li
Union Hospital, Huazhong University of Science and Technology
- SHSifei Han
China Pharmaceutical University, Monash University
- SCShi Chen
Union Hospital, Precision for Medicine (United States), Wuhan Union Hospital, Union Hospital, Huazhong University of Science and Technology
- YZYu Zhang
Precision for Medicine (United States), Wuhan Union Hospital, Union Hospital, Huazhong University of Science and Technology
Topics & keywords
- Conjugate
- Antibody-drug conjugate
- Monoclonal antibody
- Antibody
- Drug
- Linker
- Immunoconjugate
- Immunotoxin
- Good health and well-being